Literature DB >> 12379482

Differential coupling of the extreme C-terminus of G protein alpha subunits to the G protein-coupled melatonin receptors.

Janice E Drew1, Perry Barrett, Shaun Conway, Philippe Delagrange, Peter J Morgan.   

Abstract

Melatonin receptors interact with pertussis toxin-sensitive G proteins to inhibit adenylate cyclase. However, the G protein coupling profiles of melatonin receptor subtypes have not been fully characterised and alternative G protein coupling is evident. The five C-terminal residues of Galpha subunits confer coupling specificity to G protein-coupled receptors. This report outlines the use of Galphas chimaeras to alter the signal output of human melatonin receptors and investigate their interaction with the C-termini of Galpha subunits. The Galphas portion of the chimaeras confers the ability to activate adenylate cyclase leading to cyclic AMP production. Co-transfection of HEK293 cells expressing MT(1) or MT(2) melatonin receptors with Galphas chimaeras and a cyclic AMP activated luciferase construct provided a convenient and sensitive assay system for identification of receptor recognition of Galpha C-termini. Luciferase assay sensitivity was compared with measurement of cyclic AMP elevations by radioimmunoassay. Differential interactions of the melatonin receptor subtypes with Galpha chimaeras were observed. Temporal and kinetic parameters of cyclic AMP responses measured by cyclic AMP radioimmunoassay varied depending on the Galphas chimaeras coupled. Recognition of the C-terminal five amino acids of the Galpha subunit is a requisite for coupling to a receptor, but it is not the sole determinant.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379482     DOI: 10.1016/s0167-4889(02)00312-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  1 in total

1.  The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor.

Authors:  F Cogé; S P Guenin; I Fery; M Migaud; S Devavry; C Slugocki; C Legros; C Ouvry; W Cohen; N Renault; O Nosjean; B Malpaux; P Delagrange; J A Boutin
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.